| 证券代码：688277 证券简称：天智航 公告编号：2025-024 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 北京天智航医疗科技股份有限公司 | | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | | 重要内容提示： | | | | | | | | 本次会议是否有被否决议案：无 | ? | | | | | | | 会议召开和出席情况 | 一、 | | | | | | | 股东大会召开的时间：2025 年 月 20 日 | （一） | 5 | | | | | | 股东大会召开的地点：北京市海淀区建枫路（南延）中关村西三旗金隅 | （二） | | | | | | | 8 号楼北京天智航医疗科技股份有限公司会议室 | 科技园 号院 2 | | | | | | | 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | （三） | | | | | | | ...

北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 法律意见书 二〇二五年五月 法律意见书 北京市中伦（上海）律师事务所 关于苏州麦迪斯顿医疗科技股份有限公司 法律意见书 致：苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"） 北京市中伦（上海）律师事务所（以下简称"本所"）接受公司的委托，指 派律师出席并见证公司2024年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《苏州麦迪斯顿医疗科技股份有限公司章程》（以下 简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、 出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 资格、会议表决程序及表决 ...

Core Points - The implementation of the "Private Economy Promotion Law" starting from May 20 marks a significant step in recognizing the legal status of the private economy in China, aiming to enhance fair competition and strengthen property rights protection, thereby boosting the confidence of private enterprises [1] Group 1: Legislative Impact - The law emphasizes support for technological innovation and transformation of private enterprises, encouraging them to play a vital role in building a modern industrial system [1] - The law includes a dedicated chapter on "technological innovation," highlighting the potential and importance of the private economy in this area [1] - By the first quarter of 2025, over 836,000 new private enterprises in the "four new" economy (new technologies, new industries, new business formats, new models) were established, accounting for over 40% of all new private enterprises [1] Group 2: Technological Advancements - Private enterprises are making significant strides in AI technology, with DeepSeek-R1 being a notable example of a breakthrough in AI large models [2] - The rise of humanoid robots and advancements in semiconductor companies indicate a strong growth trend in the private sector's technological capabilities [2] - The integration of AI in various sectors, such as healthcare and logistics, is driving innovation and improving efficiency, with companies like Mindray and Manbang leading the way [2][3] Group 3: Financial Support - Financial support for private enterprises is increasing, with the establishment of 74 private equity investment funds aimed at supporting technological innovation [4][5] - By the end of the first quarter, the loan balance for high-tech enterprises reached 17.7 trillion yuan, reflecting a 20% year-on-year growth [5] - The law mandates improved financial services for private enterprises, promoting collaboration between banks and financing guarantee institutions [5] Group 4: Confidence Boost - The introduction of the "Private Economy Promotion Law" has significantly boosted the confidence of private enterprises, providing a strong legal safeguard for their development [6] - The law establishes a unified market access negative list system and ensures equal treatment of private enterprises in accessing resources and legal protections [6][7] - Various supporting regulations and mechanisms are being developed to facilitate the implementation of the law, enhancing the overall business environment for private enterprises [7]

Group 1 - The company has established a special account for the storage of raised funds and signed a four-party supervision agreement to ensure compliance with regulations and protect investors' rights [1][2] - The total amount raised from the issuance of convertible bonds is RMB 543.31 million, with a net amount of RMB 532.698 million after deducting related expenses [1] - The special account is designated solely for the storage and use of funds related to the medical consumables centralized operation service (SPD) project [3][4] Group 2 - The four-party supervision agreement involves the company, its subsidiaries, the underwriting institution, and the bank, ensuring proper management of the raised funds [2][3] - The agreement stipulates that any funds stored in the account must not be used for purposes other than the specified project [3] - The underwriting institution is responsible for ongoing supervision and can conduct site investigations and inquiries regarding the use of the funds [3][4]

Core Insights - OpenAI has launched HealthBench, an open-source benchmark for evaluating the performance and safety of large language models in the healthcare sector, which has sparked widespread discussion in the industry [1][3] - The benchmark was developed with the participation of 262 practicing doctors from 60 countries and integrates 5,000 real medical dialogue data, utilizing 48,562 unique scoring criteria created by doctors for meaningful open assessments [1][3] - The introduction of HealthBench is expected to enhance the scientific and comprehensive evaluation of AI medical models, accelerating the application of AI technology in healthcare and providing new development opportunities for related companies [1][3] Group 1: HealthBench Overview - HealthBench consists of 7 themes and 5 evaluation dimensions, focusing on areas such as emergency referrals and professional communication, with dimensions including accuracy and contextual understanding [3][4] - OpenAI has also introduced two special versions of HealthBench: HealthBench Consensus, which includes 34 critical evaluation dimensions verified by doctors, and HealthBench Hard, which presents more challenging assessment scenarios [4] - The credibility of HealthBench has been supported by a meta-evaluation comparing model scores with human doctor scores, showing high consistency in 6 out of 7 evaluation areas [4] Group 2: Trends in AI Healthcare Applications - The AI healthcare market is projected to grow at an annual rate of 43% from 2024 to 2032, potentially reaching a market size of $491 billion [6] - AI is expected to enhance healthcare accessibility and efficiency, addressing issues like personnel shortages in hospitals and improving diagnostic accuracy [6] - The evolution of AI in healthcare has transitioned from rule-driven to data-driven approaches, now entering a multi-modal integration phase, allowing for better understanding and modeling of diverse medical data [6][7] Group 3: Future Directions in AI Models - The focus of competition among large models has shifted from merely increasing parameter size to optimizing model efficiency and performance under limited computational resources [7] - Key trends in AI applications within the pharmaceutical industry include the emergence of models as products, local and edge deployment, and rapid expansion of AI applications in research and development [7][8] - The pharmaceutical industry is expected to see a rise in specialized models tailored for specific scenarios, enhancing the adaptability and effectiveness of AI solutions [7][8]

Group 1 - The 35th National Day for Assisting the Disabled is on May 18, 2025, with the 7th National Self-Reliance Model and Advanced Work for Assisting the Disabled Commendation Conference held in Beijing on May 16 [1] - Wuhan University of Science and Technology teacher Yuan Xin and Hubei Radio and Television Station music broadcast chief editor Li Jun were awarded the title of "National Self-Reliance Model" [1] - The Wuhan City Haoran Disabled Persons Public Service Center was recognized as a "National Advanced Collective for Disabled Persons Work" [1] Group 2 - Yuan Xin, who lost his right arm in a car accident at the age of 3, has received over 70 awards and honors during his 9 years at Wuhan University of Science and Technology, including national and provincial recognitions [1][2] - Li Jun, who became disabled due to illness, has hosted multiple award-winning programs and initiated the "Little Bee" barrier-free movie viewing service team, helping over 500 disabled individuals with employment and entrepreneurship [2] - The Wuhan City Haoran Disabled Persons Public Service Center, founded in 2017, has assisted over 300 individuals with spinal cord injuries and provided voluntary services to over 50,000 people [2] Group 3 - Chen Xiangdong, director of the anesthesiology department at Huazhong University of Science and Technology, has dedicated over 30 years to medical technology for assisting the disabled, developing sleep monitoring devices and limb assistive devices [2] - Chen's team has organized free medical consultations in remote areas, treating severe scoliosis patients and providing assistance to hospitalized disabled patients [2]

经营质效见韧性 资本市场是促进民营经济发展壮大的重要平台。目前，科创板民营企业占比超八成，市值超3.8万亿 元。 科创板民企首发募集资金超过5300亿元，资金大部分投向研发及产业化项目，加速了各领域的产业升级 与经济发展。 科创板民营企业经营质效、发展活力、投资信心实现稳步提升。2024年度，科创板民营企业合计实现营 收9091.97亿元，实现净利润225.99亿元。其中，195家科创板民营企业的营业收入、净利润双增长，41 家公司营业收入增速超50%，86家公司净利润增速超50%。 结合2024年业绩表现看，158家公司营业收入超10亿元，145家公司净利润超1亿元。部分企业实现跨越 式发展，154家公司上市后营收实现翻番，70家公司净利润实现翻倍或扭亏为盈，形成"创新—资本—产 业"的良性循环。 民营企业的回款效率是实现长期健康发展的重要基础。2024年度，科创板民营企业整体回款情况得到改 善，销售商品、提供劳务收到的现金金额合计1.05万亿元，同比增加3.7%，较收入增速高出2个百分 点。回款效率的提升进一步提高了科创板民营企业研发资金可获得性，为持续创新提供了现金流保障。 研发创新显活力 创新是科创板 ...

Financial Performance - In 2024, the company achieved operating revenue of 1,606.32 million yuan, a year-on-year increase of 1.45% [2] - The net profit attributable to the parent company was 349.68 million yuan, a decrease of 29.07% compared to the previous year [2] - Earnings per share were 0.73 yuan, down 30.48% year-on-year, primarily due to a decline in gross profit from high polymer products [3] - In Q1 2025, operating revenue was 324.86 million yuan, a decrease of 17.69% year-on-year [3] - The net profit attributable to the parent company for Q1 2025 was 80.42 million yuan, down 33.75% year-on-year, with earnings per share at 0.17 yuan, a decrease of 32.00% [3] Product Applications - PVP is used in the new energy sector as a dispersant for carbon nanotubes and in solid-state batteries for material dispersion and interface optimization [3] - In 2024, the expected shipment volume for new energy applications is over 3,000 tons, with a projected increase in 2025 [3] - PVP's application in electronic skin focuses on material modification and conductive network construction, with no large-scale shipments currently [4] Pricing and Market Impact - PVP prices have significantly decreased compared to the previous two years and are currently stabilizing [4] - The company anticipates an increase in average product prices as the proportion of high-end products rises [4] - Approximately 50% of PVP exports are to Europe, the Middle East, Southeast Asia, and India, with exports to the U.S. accounting for only 3%-5% [5] Product Overview - Euriz is a copolymer of vinyl ether/maleic anhydride, known for its linear molecular structure and good chemical stability [5] - In 2024, Euriz sales are expected to reach about 1,500 tons, with approximately 90% for export and a high unit price [5] - The estimated shipment volume for Euriz in 2025 is over 2,000 tons, with a gross profit margin of 60-70% [5]

Group 1 - The core viewpoint of the article highlights the rapid integration of large language models into the healthcare system, with 98 out of the top 100 hospitals in China claiming to have completed model deployment by April 30, 2025 [1] - Among these hospitals, 38 have developed 55 vertical medical models tailored to their specific needs based on general models [1][4] - The shift from "buyers" to "developers" indicates that doctors are becoming crucial contributors to AI development in healthcare [2][12] Group 2 - The emergence of specialized models marks a new era in healthcare AI, with hospitals increasingly focusing on vertical models that address specific diseases and clinical needs [4][6] - The DeepSeek model has significantly lowered the barriers for hospitals to deploy large models, allowing even those with no prior experience to customize and implement them [4][11] - As of April 30, 2025, there are 22 specialized vertical models in development, covering various medical fields such as cardiology, nephrology, and oncology [7][9] Group 3 - The collaboration between hospitals and enterprises remains the dominant model for developing vertical medical models, although independent hospital development is on the rise [13][15] - Major companies like Huawei, China Telecom, and iFlytek are actively involved in the development of these vertical models, indicating a trend towards increased collaboration between hospitals and tech firms [16][19] - The regulatory landscape for large models is evolving, with potential classification as medical devices requiring rigorous approval processes [19][20]